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There  is  extensive  evidence  that  breast  cancer  incidence  is 
increased in current users of menopausal hormone therapy and 
that the risk returns to that of never users of hormonal therapy 
soon after use ceases (1–4). Virtually all published reports that have 
compared the effects of different types of hormonal therapy found 
greater increases in breast cancer risk with use of estrogen–progestin 
than with use of estrogen-only formulations [see (4), which summa-
rized results from 22 studies]. Results from some studies in the United 
States (4–6), including the  Women’s Health Initiative trial, found 
little or no increase in breast cancer risk with use of estrogen-only 
preparations. However, about 90% of the women in the estrogen-
only arm of this trial were randomly assigned to hormonal therapy 
more than 5 years after their menopause, and the Women’s Health 
Initiative investigators recently reported that breast cancer risk was 
greater if hormonal therapy use began less than 5 years after meno-
pause than after a longer gap, both for estrogen-only and for estrogen
–progestin preparations (6). We investigated whether breast cancer 
incidence varied by the timing of use of different types of hormonal 
therapy in a large prospective study in the United Kingdom.
Participants and Methods
Data Collection and Follow-up
A total of 1.3 million women who were invited for screening by 
the Breast Screening Programme of the National Health Service 
were recruited into the Million Women Study from May 1, 1996, 
through  December  31,  2001.  They  completed  a  baseline   
questionnaire approximately a week before they were screened, 
which asked about sociodemographic and other factors, including 
the  use  of  hormonal  therapy  (7).  Participants  were  resurveyed 
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approximately 3 years after recruitment to update information on 
hormonal therapy use, menopausal status, and other factors. Study 
details, including the questionnaires used, can be viewed at www.
millionwomenstudy.org. All participants gave written consent to 
take part in the study, and the Oxford and Anglia Multi-Centre 
Research Ethics Committee approved the study.
Every  study  participant  had  a  unique  National  Health  Service 
number and was followed via record linkage (using that number and 
other personal details) to data held by the National Health Service 
Central Registers. These registers routinely collect nationwide infor-
mation on cancer registrations and deaths [which are coded by use of 
the International Classification of Diseases, Tenth Revision (ICD-10) (8)]. 
The registers of the National Health Service regularly provided study 
investigators with precoded data on cause-specific incident cancers and 
deaths, and the date when each was registered. Information on tumor 
characteristics was obtained from cancer registry and screening clinic 
data, as well as from pathology reports and questionnaire data (9).
Statistical Analyses
The endpoint for these analyses was breast cancer (ICD-10 codes 
C50 or D05). We excluded women with any type of invasive cancer 
(except nonmelanoma skin cancer [ICD-10 code C44]) or with in 
situ breast cancer [ICD-10 code D05] that was registered before 
recruitment (19 729 with breast cancer) and women with unknown 
hormonal  therapy  use  (247  with  breast  cancer).  Analyses  were   
further restricted to postmenopausal women (defined as those who 
reported that they had had a natural menopause or a bilateral oo-
phorectomy or those who were aged 53 years or older with an 
unknown  age  at  menopause  [ie,  those  who  started  hormonal 
therapy  or  had  a  hysterectomy  before  their  natural  menopause; 
sensitivity analyses were done to assess the effect of including such 
women]). Woman-years were calculated from the date of recruit-
ment (or, if not postmenopausal at recruitment, from the date when 
they completed a subsequent questionnaire and reported that they 
were postmenopausal or when they reached their 53rd birthday) up 
to the date of cancer registration, the date of death, 48 months after 
the last study questionnaire was completed, or December 31, 2002, 
whichever came first. Censoring at 48 months after the time of last 
contact was done to minimize misclassification of variables over 
time and the additional censoring in 2002 was done because many 
UK women ceased hormonal therapy use after the 2002 publica-
tion of the first results from the Women’s Health Initiative trial 
(10,11).
The postmenopausal women were classified as being current, 
past, or never users of hormonal therapy at the time of last contact. 
This  classification  was  done  initially  by  use  of  information 
reported  on  the  recruitment  questionnaire,  with  woman-years 
contributed to the appropriate category up to the date that they 
completed the second study questionnaire, when they were reclas-
sified by use of the updated information provided. (The second 
questionnaire was mailed to participants approximately 3 years after 
they completed the first questionnaire. By the end of 2002, the cen-
soring date for these analyses, two-thirds of the participants had been 
mailed the second questionnaire and the response was 65%.) Current 
users of hormonal therapy were classified further by the type of hor-
monal therapy last used, their age at first use of hormonal therapy, 
the interval between menopause and first use of hormonal therapy, and 
CONTEXT AND CAVEATS
Prior knowledge
Breast cancer risk has generally been found to be greater in users 
of estrogen–progestin than estrogen-only formulations of meno-
pausal hormonal therapy.
Study design
Data on use of hormonal therapy from a large prospective study of 
postmenopausal  women  in  the  United  Kingdom  were  used  to 
investigate the incidence and risk of breast cancer according to 
various aspects of hormonal therapy use.
Contribution
There was substantial heterogeneity in breast cancer risk among 
current users of both types of hormonal therapy. Starting hor-
monal therapy before or soon after the start of menopause was 
associated  with  greater  risk  of  breast  cancer  than  starting  it 
later.
Implications
The timing of the start of hormone therapy relative to that of men-
opause appears to be an important modifier of associated risk of 
breast cancer.
Limitations
Information on use of hormonal therapy was reported on average 
1.4 years before breast cancers were diagnosed, and so there could 
have been some misclassification of the use of hormone therapy 
among  both  breast  cancer  patients  and  the  population  at  risk, 
which would slightly dilute estimates of relative risk.
From the Editors
 
the total duration of hormonal therapy use. In analyses with respect 
to duration of hormonal therapy use, women were classified by the 
duration reported at last contact and, for those diagnosed with breast 
cancer, estimates were made of the actual average duration of current 
use at diagnosis. For past users of hormonal therapy at the time of 
last contact, their time since last use was estimated, by assuming that 
it increased by 1 year for every year of follow-up.
Cox regression models, which used attained age as the under-
lying time variable, were applied to estimate relative risks (RRs) 
and  the  associated  variances  for  various  aspects  of  hormonal 
therapy  use;  the  STATA  computing  package  (STATA  Corp, 
Texas, 2007, release 10.1) was used for all analyses. Analyses were 
also  stratified  by  age  at  recruitment  (<52,  53–55,  56–58, 
59–61, 62–64, or ≥65 years) and adjusted for region of residence 
(10 areas covered by 10 cancer registries, East Anglia, North West 
[Manchester  and  Lancashire],  North  West  [Mersey],  Northern 
and  Yorkshire,  Oxford,  Scotland,  South  West,  Thames,  Trent, 
West), by quintiles of socioeconomic group within the study popu-
lation, as described previously (7), age at menopause (<42, 43–47, 
48–52, or ≥53 years), parity and age at birth of first child (nullipa-
rous or 1–2 or ≥3 children, cross-classified by age at birth of first 
child <25 or ≥25 years), body mass index (<25, 25–29, or ≥30 kg/
m
2), and alcohol consumption (<10 or ≥10 g/d). For these analyses, 
it should be noted that a body mass index of less than 25 kg/m
2 was 
referred to as lean or not overweight, that of 25 kg/m
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referred  to  as  overweight,  and  that  of  30  kg/m
2  or  more  was 
referred to as obese. Those participants with missing or unknown 
values  were  assigned  to  a  separate  category  for  each  variable. 
Sensitivity analyses were done to assess the effect of additional 
adjustments, and stratified analyses were also done to assess any 
deviation from proportional hazards.
Whenever two groups were compared, relative risks and 95% 
confidence  intervals  (CIs)  are  presented.  However,  when  more 
than  two  groups  were  compared,  variances  were  estimated  by 
treating the relative risks as floating absolute risks, yielding floated 
confidence intervals (fCIs) (12). This method enabled valid com-
parisons between any two groups, even if neither was the baseline; it 
did not alter the relative risks but slightly reduced the variances at-
tributed to relative risks that were not defined as 1.0. Consequently, 
comparison between any two groups, as in the text, must take the 
variance  of  each  into  account  (13).  Standardized  breast  cancer 
incidence rates per 100 women aged 50–59 years per year were 
calculated by taking incidence rates in never users as the standard 
and  standardizing  by  age,  region,  socioeconomic  group,  age  at 
birth of first child, parity, and alcohol consumption. All statistical 
tests were two-sided.
Results
These  analyses  included  1 129 025  postmenopausal  women  who 
provided prospective information on hormonal therapy use and 
other factors relevant for breast cancer risk. Their average age at 
entry into the study was 56.6 years (SD = 4.8 years). At the time of 
last contact, 615 753 (55%) were ever users of hormonal therapy 
and  394 697  (35%)  were  current  users.  During  4.05  million 
woman-years  of  follow-up,  15 759  incident  breast  cancers  oc-
curred, 9632 (61%) in ever users and 7107 (45%) in current users 
of hormonal therapy. The breast cancers were diagnosed an av-
erage of 1.4 years after the time of last contact. Current, past, and 
never users of hormonal therapy did not differ materially by socio
demographic and other factors relevant for breast cancer (Table 1).
We had previously reported on the association between use of 
hormone therapy and breast cancer risk in this cohort (7). In this 
report, we updated information both on menopause and on use of 
hormone therapy over time, so more postmenopausal women are 
included  this  analysis  (1 129 025  vs  828 923  previously),  and  a 
greater proportion had ever used hormone therapy (55% vs 53% 
previously).  Follow-up  has  been  extended,  and  there  are  more 
incident breast cancers in these analyses (15 759 vs 7140 previ-
ously). Because exposure data were updated in this analysis, the 
average time between breast cancer diagnosis and the last recorded 
use of hormone therapy was only 1.4 years, whereas it had been   
2.6 years previously, and so misclassification of exposure in this 
analysis was less likely.
Our initial comparison was of breast cancer risk in current and 
past users of hormone therapy vs that in never users (Figure 1). 
The adjusted relative risks of breast cancer were statistically signif-
icantly  increased,  both  in  current  and  in  past  users  (Figure  1,   
P < .001 for each comparison vs never users). We then compared 
breast cancer risk among current users by the type of hormonal 
therapy used and found a statistically significant variation in risk 
across  the  types  (Pheterogeneity  <  .001);  the  greatest  excess  risk  was 
among  current  users  of  estrogen–progestin  hormonal  therapy, 
but  risk  was  also  statistically  significantly  increased  in  users  of 
estrogen-only  preparations  and  of  tibolone  (a  synthetic  steroid 
with estrogenic,  progestogenic, and androgenic activities that is 
licensed in Europe but not in the United States) (P < .001 for each 
of the three formulations compared with never users).
Although the risk of breast cancer was statistically significantly 
increased among past users of hormonal therapy (Figure 1), inci-
dence rates declined rapidly after use ceased (Figure 2). In the first 
2 years after hormonal therapy use had ceased, breast cancer risk 
was still slightly, but statistically significantly, increased (RR = 1.16, 
95% CI = 1.08 to 1.24; P < .001, on the basis of the 1003 exposed 
women who developed breast cancer in this analysis). Subsequently, 
and up to 14 years after hormonal therapy use had ceased, the risk 
in past users of hormonal therapy remained similar to that of never 
users (RR = 0.99, 95% CI = 0.93 to 1.05, on the basis of 1098 
exposed women who developed breast cancer).
The  relative  risks  of  breast  cancer  among  current  users  of 
estrogen-only  and  of  estrogen–progestin  formulations,  the  two 
most commonly used types of hormonal therapy were considerably 
lower  for  screen-detected  than  for  non–screen-detected  breast 
cancers  (Pheterogeneity  <  .001,  for  each  type)  (Figure  3).  Women 
included in these analyses were screened an average of 7.7 days 
after they completed the recruitment questionnaire. Breast cancers 
diagnosed in the first 4 months after recruitment should include 
virtually all breast cancers found at screening soon after the base-
line questionnaire was completed. Among users of the two most 
Table 1. Characteristics of the study population and details of follow-up, by last reported use of hormonal therapy (HT)
Characteristic Current HT (n = 394 697) Past HT (n = 221 056) Never HT (n = 513 272)
At recruitment    
  Mean age, y (SD) 55.1 (4.3) 56.7 (4.4) 57.7 (5.0)
  Socioeconomic status, % in upper third 34 34 32
  Mean parity, No. of children (SD) 2.1 (1.2) 2.2 (1.2) 2.1 (1.3)
  Mean age at birth of first child (for parous women), y (SD) 23.5 (4.3) 24.6 (4.2) 24.5 (4.3)
  Mean body mass index, kg/m2 (SD) 25.7 (4.4) 26.5 (4.6) 26.5 (4.9)
  Strenuous physical activity, % >once a week 40 39 37
  Mean alcohol consumption, g/wk (SD) 48 (55) 44 (53) 37 (50)
  % Current smoker 23 21 20
Follow-up for breast cancer    
  Woman-years of follow-up for incidence per 1000 women 1418.8 749.3 1885.6
  Total No. of incident breast cancers 7107 2525 6127jnci.oxfordjournals.org    JNCI | Articles 299
commonly used types of hormone therapy, the relative risks for 
breast cancer were substantially lower in the first 4 months after 
recruitment than subsequently (for current users of estrogen-only 
therapy, RR = 1.19, 95% CI = 1.09 to 1.30 in the first 4 months 
and RR = 1.50, 95% CI = 1.41 to 1.60 subsequently; and for cur-
rent  users  of  estrogen–progestin  hormonal  therapy,  the  corre-
sponding relative risks were RR = 1.41, 95% CI = 1.31 to 1.52 and 
2.32, 95% CI = 2.20 to 2.44; Pheterogeneity < .001, for each type). There 
were  also  large  differences  in  the  hormonal  therapy–associated 
risks for tumors that were estrogen receptor positive compared 
with those that were estrogen receptor negative and for low-grade 
compared with high-grade disease (Pheterogeneity ≤ .005, for each hor-
monal therapy type) (Figure 3). Users of estrogen–progestin for-
mulations were also more likely than never users to have tumors 
involving the lymph nodes than localized disease (Pheterogeneity = .009).
The association between use of the two most commonly used 
types of hormonal therapy (ie, estrogen-only and estrogen–progestin 
formulations) and risk for breast cancer was next analyzed by the 
time  when  hormone  use  began  and  by  the  duration  of  its  use 
(Figure 4). For current users of both these formulations, the risk of 
breast cancer was statistically significantly increased among women 
who started use of hormonal therapy both before age 50 years and 
at ages 50 years or older, and there were essentially no differences 
by age at starting. The risk of breast cancer associated with each 
type of hormonal therapy was also statistically significantly increased 
with hormonal therapy use for durations of less than 5 years and of 
5 years or more, respectively, but the risk was significantly greater 
with the longer duration (Pheterogeneity < .001, for each formulation). 
Among current users of tibolone, the associations were similar to 
those found for the two more commonly used hormonal therapies 
(for tibolone users, RR = 1.35, 95% CI = 1.11 to 1.64, for use be-
ginning before age 50 years, vs RR = 1.45, 95% CI = 1.29 to 1.63, 
for use beginning after age 50 years; RR = 1.20, 95% CI = 1.00   
to 1.45, for a total duration of use of <5 years, vs RR = 1.49, 95% 
CI = 1.32 to 1.69, for a total duration of use of ≥5 years.)
The excess risk of breast cancer in current users was statistically 
significantly greater if use of hormonal therapy began before or 
soon after menopause than after a longer gap (Figure 4, Pheterogeneity 
< .001, both for estrogen-only and for estrogen–progestin formu-
lations). Breast cancer risk was statistically significantly increased in 
Figure 2. Risk of breast cancer, in current users and in past users by 
time since stopping hormone therapy. Relative risks (RRs) were calcu-
lated  by  taking  never  users  of  hormone  therapy  as  the  comparison 
group (RR = 1.0), stratifying by age, and adjusting by region of resi-
dence,  socioeconomic  status,  age  at  menopause,  body  mass  index, 
age  at  birth  of  first  child,  parity,  and  alcohol  consumption.  Relative   
risks (and their floated confidence intervals [fCIs]) are represented by 
circles and lines. The dotted line represents the relative risk for all never 
users. It should be noted that, for current users, time since last use is 
effectively zero.
Figure  1.  Risk  of  breast  cancer,  by  use  of 
hormone  therapy.  Relative  risks  (RRs)  were 
calculated,  taking  never  users  of  hormone 
therapy  as  the  comparison  group  (RR  =  1.0), 
stratifying by age, and adjusting by region of 
residence, socioeconomic status, age at meno-
pause,  body  mass  index,  age  at  birth  of  first 
child, parity, and alcohol consumption. Relative 
risks  (and  their  floated  confidence  intervals 
[fCIs])  are  represented  by  squares  and  lines, 
with the area of every square being inversely 
proportional to the variance of the logarithm of 
the relative risk. This presentation thus provides 
an appropriate indication of the amount of sta-
tistical  information  involved.  The  dotted  line 
represents the relative risk for all current users 
compared with never users. * = Estimated av-
erage total duration of use of hormone therapy 
at  the  time  of  diagnosis  of  breast  cancer.   
†= Cases denote women with breast cancer.
users of estrogen-only hormonal therapy if use began before or less 
than 5 years after menopause (RR = 1.43, 95% CI = 1.35 to 1.51, P 
< .001), whereas if such use began 5 years or more after menopause, 
breast cancer risk was not increased (RR = 1.05, 95% CI = 0.89 to 
1.24, P = .6). Breast cancer risk in users of estrogen–progestin hor-
monal  therapy  was  also  statistically  significantly  greater  if  use 
began before or less than 5 years compared with 5 years or more 
after menopause (RR = 2.04, 95% CI = 1.95 to 2.14, P < .001, 
and RR = 1.53, 95% CI = 1.38 to 1.70, P < .001, respectively). 
Corresponding results for tibolone showed a similar pattern but the 
difference was not statistically significant (RR = 1.49, 95% CI = 1.33 
to 1.67, P < .001, and RR = 1.16, 95% CI = 0.92 to 1.47, P = .2).
Additional results on breast cancer risk in relation to the inter-
val between menopause and starting hormonal therapy are shown 
in Table 2. Breast cancer risk among current users of estrogen-only 300   Articles | JNCI  Vol. 103, Issue 4  |  February 16, 2011
or estrogen–progestin did not differ statistically significantly by 
whether women started using hormonal therapy either before or 
soon after menopause. Most women who had started hormonal 
therapy in the 5 years after their menopause had begun use almost 
immediately after the onset of their menopause; in this group, the 
average time between menopause and starting hormonal therapy 
was only 0.7 years for users of estrogen-only hormonal therapy and 
1.4  years  for  users  of  estrogen–progestin  hormonal  therapy. 
Figure 3. Risk of breast cancer in current users of hormone therapy by 
tumor  characteristics.  Relative  risks  (RRs)  were  calculated  by  taking 
never users of hormone therapy as the comparison group (RR = 1.0), 
stratifying by age, and adjusting by region of residence, socioeconomic 
status, age at menopause, body mass index, age at birth of first child, 
parity, and alcohol consumption. Relative risks (and their confidence 
intervals [CIs]) are represented by squares and lines, with the area of 
every  square  being  inversely  proportional  to  the  variance  of  the 
logarithm  of  the  relative  risk.  †  =  Cases  denote  women  with  breast 
cancer.
Figure 4. Risk of breast cancer in current users of estrogen-only and 
estrogen–progestin hormone therapy by the timing of first use and total 
duration of use. Relative risks (RRs) were calculated by taking never 
users of hormone therapy as the comparison group (RR = 1.0, 95% CI = 
0.97 to 1.03), stratifying by age, and adjusting by region of residence, 
socioeconomic  status,  age  at  menopause,  body  mass  index,  age  at 
birth of first child, parity, and alcohol consumption. Relative risks (and 
their floated confidence intervals [fCIs]) are represented by squares and 
lines,  with  the  area  of  every  square  is  inversely  proportional  to  the 
variance of the logarithm of the relative risk. * = Estimated average total 
duration of use of hormone therapy at the time of diagnosis of breast 
cancer. The dotted line represents the overall relative risk estimates for 
current  users  of  each  type  of  hormone  therapy.  †  =  Cases  denote 
women with breast cancer.jnci.oxfordjournals.org    JNCI | Articles 301
Among women who started hormonal therapy 5 years or more 
after menopause, the average time between menopause and start-
ing  hormonal  therapy  was  10.3  years  for  estrogen-only  and   
9.3  years  for  estrogen–progestin  formulations.  Women  who 
started hormonal therapy before their menopause had, by defini-
tion, an unknown age at menopause. To assess how this affected 
the results, we did sensitivity analyses restricted to women with a 
known age at menopause (natural or bilateral oophorectomy) who 
started  hormonal  therapy  after  menopause.  The  risk  estimates 
among  these  women  were  similar  to  those  observed  among  all 
women (Table 2). We also did sensitivity analyses to assess the ef-
fect  of  not  adjusting  for  age  at  menopause  and  found  that  the 
estimates were very slightly lower in the unadjusted analysis than 
the  adjusted  analysis  (eg,  among  women  who  started  hormonal 
therapy after a natural menopause or bilateral oophorectomy, the 
unadjusted vs adjusted values were RR = 1.35 vs RR = 1.40 for 
estrogen-only use beginning <5 years after menopause and were 
RR = 0.94 vs RR = 1.08 for estrogen-only use beginning ≥5 years 
after menopause; and corresponding unadjusted vs adjusted values 
among users of estrogen–progestin hormonal therapy were RR = 
2.06 vs RR = 2.05 and RR = 1.47 vs RR = 1.61, respectively).
The average duration of hormonal therapy use was longer in 
women who started hormonal therapy less than 5 years after men-
opause than after a longer gap (Figure 4). However, the greater 
risk among those who started hormonal therapy at around the time 
of menopause was consistently observed for both short and long 
duration use of each hormonal therapy type (Table 2). The relative 
risk estimates in Table 2 with respect to duration of use were not 
adjusted  by  age  at  menopause  because  among  current  users  of 
hormonal therapy of a given age, age at menopause and time from 
menopause  to  starting  hormonal  therapy  were  completely  con-
founded  with  duration  of  hormonal  therapy  use.  Sensitivity 
analyses of the effect of adjusting for age at menopause (see above) 
suggested that omission of this variable in the model was unlikely 
to have materially affected the results.
Among never users of hormonal therapy, the standardized inci-
dence rate for breast cancer at age 50–59 years was 0.30% (95% 
CI = 0.29% to 0.31%) per year. For users of estrogen-only hor-
monal therapy aged 50–59 years beginning use before or less than 
5 years after menopause, the standardized incidence rate was 0.43% 
(95% CI = 0.42% to 0.45%), and for such use beginning 5 years or 
more  after  menopause,  the  standardized  incidence  rate  did  not 
differ  statistically  significantly  from  that  of  never  users  (ie, 
standardized incidence rate = 0.32%, 95% CI = 0.27% to 0.37%). 
The corresponding standardized incidence rates for estrogen–pro-
gestin hormonal therapy were 0.61% (95% CI = 0.59% to 0.64%) 
and 0.46% (95% CI = 0.41% to 0.51%).
As expected, breast cancer incidence rates among never users of 
hormone  therapy  increased  with  body  mass  index  (Figure  5). 
However, contrary to the trends among never users of hormonal 
therapy, standardized incidence rates among current users of hor-
monal therapy varied little by body mass index (Figure 5). The 
different relationships between breast cancer incidence and body 
mass index among never users and among current users mean that 
the proportionate increase in risks for breast cancer associated with 
use  of  hormonal  therapy  was  greater  among  lean  women  than 
among obese women (eg, for current users of estrogen-only hor-
monal therapy, RR = 1.65, 95% CI = 1.53 to 1.78 among lean 
women and RR = 1.22, 95% CI = 1.13 to 1.31 among overweight 
and obese women) (Figure 6). Within subgroups defined by their 
body mass index, risks of breast cancer were still statistically signif-
icantly greater if hormonal therapy use began at around the time 
of menopause than after a longer gap (Figure 6). Among over-
weight and obese current users of estrogen-only hormonal therapy, 
no  statistically  significant  increase  in  breast  cancer  risk  was 
observed  if  hormonal  therapy  use  began  5  years  or  more  after 
menopause (RR = 0.91, 95% CI = 0.73 to 1.14, P = .4).
Apart from body mass index, none of the adjustment factors 
substantially modified the effect of hormonal therapy on breast 
cancer risk. Additional adjustment by other factors associated with 
Table 2. Associations between risk of breast cancer among current users of estrogen-only hormonal therapy (HT) and among current 
users of estrogen–progestin HT, by time between menopause and starting HT*
Timing of HT use
Estrogen-only HT Estrogen–progestin HT
No. RR* (95% CI) No. RR* (95% CI)
Women who started HT      
  Before menopause 1091 1.49 (1.40 to 1.58) 2364 2.10 (2.00 to 2.20)
  <5 y after menopause 833 1.36 (1.27 to 1.46) 1464 1.99 (1.89 to 2.10)
  ≥5 y after menopause 151 1.05 (0.90 to 1.24) 364 1.53 (1.38 to 1.69)
Women with a natural menopause or bilateral oophorectomy,  
    who started HT after menopause
     
  <5 y after menopause 663 1.40 (1.30 to 1.52) 1427 2.05 (1.94 to 2.17)
  ≥5 y after menopause 97 1.08 (0.88 to 1.31) 336 1.61 (1.44 to 1.79)
Women with duration of HT use of <5 years, who started HT      
  Before or <5 y after menopause 474 1.31 (1.19 to 1.43) 1206 1.76 (1.66 to 1.87)
  ≥5 y after menopause 69 0.86 (0.68 to 1.09) 192 1.34 (1.16 to 1.54)
Women with duration of HT use of ≥5 years, who started HT      
  Before or <5 y after menopause 1441 1.36 (1.29 to 1.43) 2605 2.27 (2.18 to 2.36)
  ≥5 y after menopause 81 1.09 (0.88 to 1.36) 170 1.65 (1.42 to 1.92)
*  Relative risks (RRs) were calculated by taking never users of HT as the comparison group (RR = 1.0) stratifying by age and adjusting by region of residence, 
socioeconomic status, body mass index, parity, age at first birth, and alcohol consumption; except for analyses by duration of HT use results are also adjusted by 
age at menopause. Small numbers of women with breast cancer (10 using estrogen-only HT and 19 using estrogen–progestin HT) had missing information on 
duration of HT use and were not included in analyses relating to duration of use.302   Articles | JNCI  Vol. 103, Issue 4  |  February 16, 2011
breast cancer risk, including age at menarche, height, and having a 
first-degree relative with breast cancer, did not alter the main find-
ings. Also use of analyses that stratified rather than adjusted for 
potential  confounders  gave  very  similar  results  to  those  in  this 
analysis, indicating that there was little deviation from the assump-
tion of proportional hazards.
Discussion
In this large prospective study, we found substantial and clinically 
important  heterogeneity  in  the  effects  of  hormonal  therapy  on 
breast cancer incidence among postmenopausal women. Among 
current users of hormonal therapy, there were independent effects 
of the type of hormonal therapy used, the time between meno-
pause and first use of hormonal therapy, and the duration of hor-
monal therapy use. Some of these findings confirm what is already 
well known, for example, that current users of estrogen–progestin 
preparations are at the greatest risk of breast cancer and that the 
associated risk increases with duration of use (1–4). We have pre-
viously reported (7) such findings in this cohort, but with updated 
information on hormonal therapy use and menopausal status and 
extended follow-up, these analyses include more postmenopausal 
Figure  5.  Standardized  incidence  rates  for 
breast  cancer  in  current  users  of  hormone 
therapy by the type of hormone therapy used 
and women’s body mass index. Standardized 
incidence  rates  per  100  women  aged  50–59 
years per year were calculated by taking never 
users of hormone therapy as the standard and 
standardizing by age, region of residence, so-
cioeconomic status, age at menopause, age at 
birth  of  first  child,  parity,  and  alcohol  con-
sumption.  It  should  be  noted  that  incidence 
rates are plotted against the mean body mass 
index within each subgroup. 95% confidence 
intervals are shown (error bars).
Figure  6.  Risk  of  breast  cancer  in  current  users  estrogen-only  and 
estrogen–progestin hormone therapy, by the timing of first use and 
women’s  body  mass  index.  Relative  risks  (RRs)  were  calculated  by 
taking never users of hormone therapy as the comparison group (RR = 
1.0),  stratifying  by  age,  and  adjusting  by  region  of  residence,  socio
economic status, age at menopause, body mass index, age at birth of 
first child, parity, and alcohol consumption. Relative risks (and their 
floated  confidence  intervals  [fCIs])  are  represented  by  squares  and 
lines,  with  the  area  of  every  square  is  inversely  proportional  to  the 
variance of the logarithm of the relative risk. * = Estimated average total 
duration of use of hormone therapy at the time of diagnosis of breast 
cancer. The dotted line represents the overall relative risk estimates for 
current  users  of  each  type  of  hormone  therapy.  †  =  Cases  denote 
women with breast cancer.jnci.oxfordjournals.org    JNCI | Articles 303
women, a greater number of ever users of hormone therapy, and 
more  incident  breast  cancers,  with  a  shorter  time  between  last 
reporting hormone use and the diagnosis of breast cancer. As well 
we presented new analyses showing that the interval between men-
opause  and  initiating  hormonal  therapy  use  has  an  important 
modifying effect on breast cancer risk.
The  Million  Women  Study  includes  one  in  every  four  UK 
women who were aged 50–64 years at the time of recruitment. The 
characteristics  of  the  study  population  are  similar  to  those  of 
women of a comparable age in the United Kingdom, with slightly 
greater proportions using hormonal therapy [33% at recruitment 
vs  31%  nationwide  (7,11)]  and  from  the  upper  socioeconomic 
classes (28% from the top socioeconomic quintile in the recruit-
ment areas) than in the general UK population. All study partici-
pants  were  followed  by  record  linkage  to  routinely  collected 
national cancer registration and death data. Information on cancer 
site  and  date  of  diagnosis  was  coded  before  notification  to  the 
study investigators, thus providing nondifferential ascertainment 
of incident cancers. To minimize differential reporting of expo-
sures, information on hormonal therapy use was collected before 
any  diagnosis  of  cancer  and  updated  whenever  possible  during 
follow-up.  [There  is  excellent  agreement  between  women’s 
reported use of hormonal therapy and general practitioner pre-
scription records (14).]
A limitation of this study is that information on use of hormonal 
therapy was reported an average of 1.4 years before the breast can-
cers were diagnosed. Over this period, an estimated 97% of those 
classified as never users of hormonal therapy would still have been 
never users, and 88% of those classified as current users would still 
have  been  current  users.  Such  residual  misclassification  of  hor-
monal therapy use would slightly dilute the estimates of relative risk 
but would not produce spurious associations. Correcting for such 
misclassification, by use of the regression dilution approach (15), 
would increase the logarithm of the relative risk among current 
users of either type by a factor of approximately 1.2.
We found that the risks of breast cancer associated with hor-
monal  therapy  were  considerably  lower  for  screen-detected 
breast  cancers  than  for  non–screen-detected  breast  cancers 
(Figure 3), consistent with findings from meta-analyses (16,17), 
showing that use of hormonal therapy decreases mammographic 
sensitivity and specificity. The greater risks for estrogen receptor–
positive than estrogen receptor–negative breast cancer have also 
been reported previously (18), as has a greater risk of lymph node 
involvement  in  users  of  estrogen–progestin  therapy  (19).  It 
has been suggested that part of the increased hormone therapy–
associated risk of breast cancer observed in this study may have 
resulted from selective recruitment of hormonal therapy users 
who  already  had  symptoms  of  breast  cancer.  If  that  had  hap-
pened,  there  would  have  been  a  greater  excess  of  hormonal 
therapy–associated  breast  cancer  soon  after  recruitment  than 
subsequently. However, the opposite was found: the risk of breast 
cancer was lower in the first 4 months after recruitment than   
afterward  (RR  =  1.19  vs  RR  =  1.50,  for  estrogen-only;  and 
RR  =  1.41  vs  RR  =  2.32,  for  estrogen–progestin  hormonal 
therapy), largely reflecting the lower hormonal therapy–associated 
risks observed for screen-detected breast cancers than for non–
screen-detected breast cancers.
That hormonal therapy–associated relative risks for breast cancer 
were attenuated among overweight and obese women has been 
found  in  many  studies  (3,4,9).  However,  when  incidence  rates, 
rather than relative risks, were calculated, it was clear that this 
apparent attenuation was driven by adiposity-related breast cancer 
incidence among never users of hormonal therapy. Among never users, 
but  not  among  users  of  hormonal  therapy,  incidence  rates  for 
breast  cancer  increased  with  increasing  adiposity  (Figure  5). 
Hence,  the  proportionate  increase  in  breast  cancer  risk  among 
hormone users was smaller among overweight and obese women 
than among leaner women. Circulating levels of endogenous estro-
gens increase with increasing body mass index among nonusers of 
hormonal therapy, and this observation explains most, if not all, of 
the increased risk of postmenopausal breast cancer with increasing 
adiposity  (20).  Because  endogenous  estrogen  levels  normally 
increase with adiposity among postmenopausal women, it seems 
plausible that hormonal therapy would change women’s net expo-
sure to sex hormones to a greater extent among leaner women than 
among obese women. Indeed, among obese women using estro-
gen-only hormonal therapy, breast cancer incidence rates did not 
differ statistically significantly from those of never users (Figure 5).
The  epidemiological  evidence  has  consistently  shown  that 
breast cancer risk among users of hormonal therapy returns to that 
of never users soon after use ceases (1–4), as is illustrated in Figure 
2. The observed decline in breast cancer incidence rates in the 
United States and many other countries after 2002 that followed 
reductions in the prevalence of hormonal therapy use (21,22) pro-
vides independent support for the epidemiological data. If use of 
hormonal therapy merely accelerated the presentation of preexis-
tent breast cancers, incidence rates in past users would be expected 
to fall well below those of never users. However, no marked reduc-
tion in breast cancer risk was observed after hormonal therapy use 
ceased  (Figure  2),  indicating  that  the  breast  cancers  diagnosed 
while  women  used  hormonal  therapy  were  not  just  those  that 
would have occurred anyway.
A new finding of this study, which has been little investigated 
previously, is that the interval between menopause and starting 
hormonal therapy has a substantial effect on breast cancer risk. A 
similar finding was first reported by  Women’s Health Initiative 
investigators (6), and results from a French study (23) suggested 
possible similar associations, but only in certain subgroups. In this 
large study, we found greater risks of breast cancer if hormonal 
therapy use began either before or soon after menopause than after 
a longer gap; and this pattern of risk was seen across different types 
of hormonal therapy, among women who used hormonal therapy 
for either short or long durations, and also in lean and in over-
weight and obese women. The findings were similar when various 
sensitivity  analyses  were  done,  such  as  restricting  analyses  to 
women with a bilateral oophorectomy or natural menopause who 
started hormonal therapy after their menopause.
The substantial heterogeneity in hormonal therapy–associated 
risks of breast cancer that we found, with independent effects of 
the type of hormonal therapy used, the interval between menopause 
and  starting  hormonal  therapy,  and  the  duration  of  hormonal 
therapy use could well account for much of the apparent variation 
in hormonal therapy–associated risks across studies (4). The popu-
lations that have been studied vary in terms of the prevalence of 304   Articles | JNCI  Vol. 103, Issue 4  |  February 16, 2011
obesity  and  the  interval  between  menopause  and  starting  hor-
monal therapy. For example, in the  Women’s Health Initiative 
randomized trials, some 80% of participants were overweight or 
obese (5,10) and approximately 90% were randomly assigned to 
hormonal  therapy  5  years  or  more  after  their  menopause  (6). 
Among users of estrogen-only hormonal therapy, we found little 
or no increase in the risk of breast cancer among overweight or 
obese women who started hormonal therapy 5 years or more after 
menopause (RR = 0.91, 95% CI = 0.73 to 1.14), consistent with 
findings from the Women’s Health Initiative trial (RR = 0.77, 95% 
CI  =  0.59  to  1.01)  (10).  The  corresponding  value  for  users  of 
estrogen–progestin  hormonal  therapy  in  our  data  (RR  =  1.39, 
95% CI = 1.18 to 1.64) was also consistent with findings from the 
Women’s Health Initiative trial (RR = 1.26, 95% CI = 1.00 to 
1.59) (5). Moreover, breast cancer incidence rates in the estrogen–
progestin randomized trial were similar to those observed here 
(0.46% per year in this study for use beginning 5 years or more 
after menopause and 0.43% per year in the randomized trial vs 
0.3% per year in nonusers of hormone therapy both in this study 
and in the trial). However, breast cancer incidence rates in this 
study were highest among current users of estrogen–progestogen 
who began use less than 5 years after menopause (0.61% per year), 
and no comparable randomized data are available because the large 
majority of women were randomly assigned to estrogen–progestin 
more than 5 years after their menopause (6). Hence, the findings 
from randomized trials of hormonal therapy with respect to breast 
cancer risk may not apply to women who start using hormonal 
therapy at around the time of their menopause.
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